Discovery of Novel Glutaminase (GLS1) and Histone Deacetylase (HDAC) Dual Inhibitors as a Promising Strategy for Cancer Therapy
Journal of Medicinal Chemistry · 2026
DOI: 10.1021/acs.jmedchem.6c01288 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2026. Verfasst von Zhisheng Zhang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing211198, P. R. China. Hauptthemen laut MEDLINE: Glutaminase, Histone Deacetylase Inhibitors, Antineoplastic Agents, Histone Deacetylases. Die Arbeit nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China (NSFC), Natural Science Foundation of Jiangsu Province, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Glutaminase 1 (GLS1) and histone deacetylases (HDACs) are important targets involved in cancer metabolism and epigenetic regulation, respectively. Herein, we report the design, synthesis, and biological evaluation of first-in-class GLS1/HDAC dual inhibitors as a single-molecule strategy for cancer therapy. Through systematic structure-activity relationship studies and biochemical profiling, compound 58 was identified as a promising dual inhibitor with moderate GLS1 inhibition and potent HDAC activity, particularly against HDAC6. Compound 58 exhibited strong antiproliferative activity in multiple cancer cell lines and modulated GLS1-associated glutamine metabolism and HDAC-related acetylation markers in cells. In a CT26 tumor-bearing mouse model, compound 58 achieved a tumor growth inhibition (TGI) rate of 91.10% without obvious systemic toxicity. Overall, this study supports GLS1/HDAC dual inhibition as a promising anticancer strategy and provides compound 58 as a valuable lead for further optimization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing211198, P. R. China.
- Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing211198, P. R. China.
- Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing210006, P. R. China.
ORCID-Profile: Jinlei Bian, Zhiyu Li, Xi Xu
Förderung
- National Natural Science Foundation of China (NSFC)
- Natural Science Foundation of Jiangsu Province
- Fundamental Research Funds for the Central Universities
- National College Students Innovation and Entrepreneurship Training Program
- Youth Science and Technology Talent Support Program of Jiangsu Province
Zitieren
APA
Zhang, Z., Zhang, X., Jiang, Y., Zhang, M., Zhao, J., Li, T., Yang, J., Shi, S., Cao, X., Jiang, L., Tian, Z., Wu, Y., Ru, J., Zhu, L., Du, Q., Bian, J., Li, Z., Xu, X., & Wang, J. (2026). Discovery of Novel Glutaminase (GLS1) and Histone Deacetylase (HDAC) Dual Inhibitors as a Promising Strategy for Cancer Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.6c01288
Vancouver
Zhang Z, Zhang X, Jiang Y, Zhang M, Zhao J, Li T, et al. Discovery of Novel Glutaminase (GLS1) and Histone Deacetylase (HDAC) Dual Inhibitors as a Promising Strategy for Cancer Therapy. Journal of Medicinal Chemistry. 2026. doi:10.1021/acs.jmedchem.6c01288
BibTeX
@article{Zhang2026,
author = {Zhang, Zhisheng and Zhang, Xuan and Jiang, Yinan and Zhang, Manqi and Zhao, Juan and Li, Tianxin and Yang, Jiani and Shi, Shengnan and Cao, Xueling and Jiang, Lingxiang and Tian, Zihan and Wu, Yongsheng and Ru, Jiawen and Zhu, Liuxiang and Du, Qianming and Bian, Jinlei and Li, Zhiyu and Xu, Xi and Wang, Jubo},
title = {Discovery of Novel Glutaminase (GLS1) and Histone Deacetylase (HDAC) Dual Inhibitors as a Promising Strategy for Cancer Therapy},
journal = {Journal of Medicinal Chemistry},
year = {2026},
doi = {10.1021/acs.jmedchem.6c01288}
}
EUVIMED